Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: A randomised study

European Respiratory Journal

Volumn 34, Issue 6, 2009, Pages 1364-1375

  Stolz, D ^a,e,f   Smyrnios, N ^f   Eggimann, P ^b   Pargger, H ^a   Thakkar, N ^f   Siegemund, M ^a   Marsch, S ^a   Azzola, A ^c   Rakic, J ^a   Mueller, B ^d   Tamm, M ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c Regional Hospital   (Switzerland)

^d Harvard School of Public Health ^*  (Switzerland)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f UMASS MEMORIAL MEDICAL CENTER   (United States)

Author keywords

Antibiotic therapy; Biomarker; Procalcitonin; Ventilator associated pneumonia

Indexed keywords

ANTIBIOTIC AGENT; PROCALCITONIN;

ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; BACTERIUM CULTURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VENTILATOR ASSOCIATED PNEUMONIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CALCITONIN; FEMALE; GUIDELINES AS TOPIC; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, VENTILATOR-ASSOCIATED; PROPORTIONAL HAZARDS MODELS; PROTEIN PRECURSORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 73249128024     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00053209     Document Type: Article

References (42)

1. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32: 470-485.
2. Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 1995; 274: 639-644.
3. Kollef MH. Ventilator-associated pneumonia. A multivariate analysis. JAMA 1993; 270: 1965-1970.
4. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002; 165: 867-903.
5. Rello J, Ollendorf DA, Oster G, et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 2002; 122: 2115-2121.
6. Warren DK, Shukla SJ, Olsen MA, et al. Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. Crit Care Med 2003; 31: 1312-1317.
7. Soo Hoo GW, Wen YE, Nguyen TV, et al. Impact of clinical guidelines in the management of severe hospital-acquired pneumonia. Chest 2005; 128: 2778-2787.
8. Porzecanski I, Bowton DL. Diagnosis and treatment of ventilator- associated pneumonia. Chest 2006; 130: 597-604.
9. Michaud S, Suzuki S, Harbarth S. Effect of design-related bias in studies of diagnostic tests for ventilator-associated pneumonia. Am J Respir Crit Care Med 2002; 166: 1320-1325.
10. Koenig SM, Truwit JD. Ventilator-associated pneumonia: diagnosis, treatment, and prevention. Clin Microbiol Rev 2006; 19: 637-657.
11. Rello J, Gallego M, Mariscal D, et al. The value of routine microbial investigation in ventilator-associated pneumonia. Am J Respir Crit Care Med 1997; 156: 196-200.
12. Fagon JY, Chastre J, Wolff M, et al. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial. Ann Intern Med 2000; 132: 621-630.
13. Kollef MH, Sherman G, Ward S, et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999; 115: 462-474.
14. Trouillet JL, Chastre J, Vuagnat A, et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 1998; 157: 531-539.
15. Ibrahim EH, Ward S, Sherman G, et al. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med 2001; 29: 1109-1115.
16. Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003; 290: 2588-2598.
17. Singh N, Rogers P, Atwood CW, et al. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000; 162: 505-511.
18. Dennesen PJ, van der Ven AJ, Kessels AG, et al. Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. Am J Respir Crit Care Med 2001; 163: 1371-1375.
19. Kollef MH. Microbiological diagnosis of ventilator-associated pneumonia - using the data to optimize clincial outcomes. Am J Respir Crit Care Med 2008; 173: 1182-1183.
20. Kollef MH. Providing appropriate antimicrobial therapy in the intensive care unit: surveillance vs. de-escalation. Crit Care Med 2006; 34: 903-905.
21. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416.
22. Morrow LE, Shorr AF. The seven deadly sins of ventilator-associated pneumonia. Chest 2008; 134: 225-226.
23. Muller B, Becker KL, Schachinger H, et al. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med 2000; 28: 977-983.
24. Becker KL, Nylen ES, White JC, et al. Clinical review 167: Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab 2004; 89: 1512-1525.
25. Luyt CE, Combes A, Reynaud C, et al. Usefulness of procalcitonin for the diagnosis of ventilator-associated pneumonia. Intensive care Med 2008; 34: 1434-1440.
26. Pelosi P, Barassi A, Severgnini P, et al. Prognostic role of clinical and laboratory criteria to identify early ventilator-associated pneumonia in brain injury. Chest 2008; 134: 101-108.
27. Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004; 363: 600-607.
28. Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006; 174: 84-93.
29. Stolz D, Christ-Crain M, Bingisser R, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007; 131: 9-19.
30. Nobre V, Harbarth S, Graf JD, et al. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med 2008; 177: 498-505.
31. Stolz D, Stulz A, Muller B, et al. BAL neutrophils, serum procalcitonin, and C-reactive protein to predict bacterial infection in the immunocompromised host. Chest 2007; 132: 504-514.
32. Altman DG, Schulz KF, Moher D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001; 134: 663-694.
33. BioMed CentralProcalcitonin for discontinuation of antibiotic therapy in clinically diagnosed ventilator associated pneumonia. www.controlled-trials.com/ ISRCTN61015974 Date last acessed: October 15, 2009.
34. Nylen ES, Muller B, Becker KL, et al. The future diagnostic role of procalcitonin levels: the need for improved sensitivity. Clin Infect Dis 2003; 36: 823-824.
35. Kollef MH, Morrow LE, Niederman MS, et al. Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia. Chest 2006; 129: 1210-1218.
36. Luna CM, Blanzaco D, Niederman MS, et al. Resolution of ventilator-associated pneumonia: prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Crit Care Med 2003; 31: 676-682.
37. Shorr AF, Sherner JH, Jackson WL, et al. Invasive approaches to the diagnosis of ventilator-associated pneumonia: a meta-analysis. Crit Care Med 2005; 33: 46-53.
38. Rello J, Vidaur L, Sandiumenge A, et al. De-escalation therapy in ventilator-associated pneumonia. Crit Care Med 2004; 32: 2183-2190.
39. Wanner GA, Keel M, Steckholzer U, et al. Relationship between procalcitonin plasma levels and severity of injury, sepsis, organ failure, and mortality in injured patients. Crit Care Med 2000; 28: 950-957.
40. Harbarth S, Holeckova K, Froidevaux C, et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 2001; 164: 396-402.
41. Luyt CE, Guerin V, Combes A, et al. Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 48-53. 42 Seligman R, Meisner M, Lisboa TC, et al. Decreases in procalcitonin and C-reactive protein are strong predictors of survival in ventilator-associated pneumonia. Crit Care 2006; 10: R125.
42. Suprin E, Camus C, Gacouin A, et al. Procalcitonin: a valuable indicator of infection in a medical ICU?Intensive Care Med 2000; 26: 1232-1238.